Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00365183
Recruitment Status : Terminated
First Posted : August 17, 2006
Last Update Posted : October 31, 2013
Information provided by (Responsible Party):
Pharmacyclics LLC.